Based in Chicago, Illinois, AveXis is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in a Phase 1 clinical trial for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality. SMA Type 1 is a lethal genetic disorder characterized by motor neuron loss and associated muscle deterioration, resulting in mortality or the need for permanent ventilation support before the age of two for greater than 90% of patients. We are passionately committed to moving gene therapies into the clinical setting for patients and families devastated by rare and orphan neurological genetic diseases. With the support of industry and academic alliances, we're advancing cutting-edge science in order to treat rare and life-threatening genetic diseases—starting with our clinical-stage, proprietary gene therapy candidate, AVXS-101. How to reach us: AveXis, Inc. 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: info@avexis.com Office Phone: 847.572.8280 Toll-free Phone: 844.4.AVEXIS (844.428.3947)
View Top Employees from AveXis, Inc.Website | https://www.novartis.com/our-company/novartis-pharmaceuticals/novartis-gene-therapies |
Ticker | NASDAQ:AVXS |
Revenue | $297 million |
Funding | $170.5 million |
Employees | 220 (185 on RocketReach) |
Founded | 2010 |
Address | 2275 Half Day Rd, Ste 300, Bannockburn, Illinois 60015, US |
Phone | (847) 572-8280 |
Technologies |
JavaScript,
HTML,
PHP
+67 more
(view full list)
|
Industry | Biotechnology, Pharmaceuticals, Drug Discovery, Gene Therapy, Science and Engineering, Synthetic Biology, Design, Healthcare, Health Care, Spinal Muscular Atrophy, Medical |
Web Rank | 867925 |
Web Visits | 73720 |
Keywords | Avexis, Avexxis, Avexis Sma Aav9 Self Complementary, Avexis Portfolio, Zolgensma Smn1 Pdf |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 541 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular AveXis, Inc. employee's phone or email?
The AveXis, Inc. annual revenue was $297 million in 2023.
Jim Goff is the Vice President, Investor Relations and Corporate Communications of AveXis, Inc..
185 people are employed at AveXis, Inc..
AveXis, Inc. is based in Bannockburn, Illinois.
The NAICS codes for AveXis, Inc. are [5417, 54, 32, 325, 541, 3254, 32541].
The SIC codes for AveXis, Inc. are [283, 28].